Reduced susceptibility to IL-1 and endotoxin in transgenic mice expressing IL-1 in their lens

Cytokine

Volumn 8, Issue 4, 1996, Pages 288-293

  Lai, James C ^a,b   Wawrousek, Eric F ^a   Sipe, Jean D ^c   Whitcup, Scott M ^a   Gery, Igal ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endotoxin effects; IL 1 transgene; Responses to IL 1; Transgenic mice

Indexed keywords

ALPHA CRYSTALLIN; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; MESSENGER RNA; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EYE INFLAMMATION; LENS; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECOMBINANT GENE; THYMOCYTE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

EID: 0029925296     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0038     Document Type: Article

References (30)

1. Durum SK, Schmidt JA, Oppenheim JJ (1986) Interleukin 1: an immunological perspective. Annu Rev Immunol 3:263-287.
2. Dinarello CA. Interleukin-1 and interleukin-1 antagonism (1991) Blood 77:1627-1652.
3. Stadnyk AW (1994) Cytokine production by epithelial cells. FASEB J 8:1041-1047.
4. Bernard C, Tedgui A (1992) Cytokine network and the vessel wall. Insights into septic shock pathogenesis. Eur Cytokine Netw 3:19-33.
5. Wawrousek EF, Lai JC, Gery I, Chan CC (1994) Progressive inflammatory disease and neovascularization in the eyes of interleukin -1β transgenic mice. In Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (eds) Advances in Ocular Immunology. Elsevier, Amsterdam, pp 143-146.
6. Allison J, McClive P, Baxter A, Morahan G, Miller J (1995) Acceleration of diabetes in the NOD mouse by in situ IL-2. J Cell Biochem (suppl) 21:135.
7. Wawrousek EF, Chepelinsky AB, McDermott JB, Piatigorsky J (1990) Regulation of the murine alpha A-crystallin promoter in transgenic mice. Dev Biol 137: 68-76.
8. Sipe JD (1989) The molecular biology of interleukin 1 and the acute phase response. Adv Intern Med 34:1-20.
9. Baumann H, Gauldie J (1994) The acute phase response. Immunol Today 15:74-80.
10. Steel DM, Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15: 81-88.
11. Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR (1985) Pretranslational modulation of acute hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med 162:930-942.
12. Rokita H, Neta R, Sipe JD (1993) Increased fibrinogen synthesis in mice during the acute phase response: cooperative interaction of interleukin 1, interleukin 6, and interleukin 1 receptor antagonist. Cytokine 5:454-458.
13. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552.
14. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, Towne E, Tracey D, Wardwell S, Wei FY, Wong W, Kamen R, Seshadri T (1995) Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80:401-411.
15. Dinarello CA (1992) Role of interleukin 1 in infectious diseases. Immunol Rev 127:119-146.
16. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassali P, Loetscher H (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Europ J Immunol 21:2883-2886.
17. Hack EC, De Groot ER, Felt-Bersma JF, Nuijens JH, Strack Van Schijndel RJM, Eerenberg-Belmer AJM, Thijs LG, Aarden LA (1990) Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710.
18. Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829-1835.
19. Jacobs C, Young D, Tyler S, Callis G, Gillis S, Conlon PJ (1988) In vivo treatment with IL-1 reduces the severity and duration of antigen-induced arthritis in rats. J Immunol 141:2967-2974.
20. Wallach D, Holtmann H, Engelmann H, Nophar Y (1988) Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 140:2994-2999.
21. van der Meer JWM, Barza M, Wolff SM, Dinarello CA (1988) Low dose recombinant interleukin-1 protects granulocytopenic mice from Gram-negative infection. Proc Natl Acad Sci USA 85:1620-1623.
22. Morrissey PJ, Charrier K (1994) Treatment of mice with IL-1 before infection increases resistance to a lethal challenge with Salmonella typhimurium. The effect correlates with the resistance allele at the Ity locus. J Immunol 153:212-219.
23. Bogels MTE, Mensink EJBM, Ye K, Boerman OC, Vershneren CMM, Dinarello CA, van der Meer JWM (1994) Differential gene expression for IL-1I receptor antagonist, IL-1, and TNF receptor and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. J Immunol 153:5772-5780.
24. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MC, Norton JA (1991) Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram negative sepsis. J Clin Invest 88:34-39.
25. DeForge LE, Takeuchi E, Nguyen DT, Remick DG (1994) Immunological priming attenuates the in vivo pathophysiological response to lipopolysaccharide. Comparison of cytokine production, tissue injury, and lethality in complete Freund's adjuvant-primed mice and in unprimed mice. Am J Path 144:599-611.
26. Ye K, Koch KC, Clark BD, Dinarello CA (1992) Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type 1 by destabilizing its mRNA, whereas interleukin-2 increases its expression. Immunology 75:427-434.
27. Arend WP (1993) Interleukin-1 receptor antagonist. Adv Immunol 54:167-227.
28. Kransney PA, Young PR (1992) Further aspects of IL-1β secretion revealed by transfected monkey kidney cells. Cytokine 4:134-143.
29. Sipe JD, Gonnerman WA, Loose LD, Knapschaefer G, Franzblau C. (1989) Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Meth 125:125-135.
30. Gery I, Davies P, Derr J, Krett N, Barranger JA (1981) Relationship between production and release of lymphocyte activating factor (interleukin 1) by macrophages. I. Effects of various agents. Cell Immunol 64:293-303.